SMAP-2 (C09-1170-061)

SMAP-2 (DT-1154) is an orally active protein phosphatase 2A (PP2A) activator, with anti-cancer activityIn VitroSMAP-2 reduces cell viability of pancreatic ductal adenocarcinoma (PDA) cell lines in a dose-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoSMAP-2 significantly reduces abdominal aortic aneurysms (AAA) incidence and aortic dilation in pro-AAA apolipoprotein E- (ApoE-/-) mice. SMAP-2 (15 mg/kg; i.g.; daily; 6 days a week; for approximately 14 days) has anti-tumor activity in pancreatic cancer mice model. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: NSG mice, with PANC89 cells xenograftDosage: 15 mg/kg Administration: Oral gavage, daily, 6 days a week, for approximately 14 days Result: Decreased tumor growth and tumor weight.Form:SolidIC50& Target:PP2A. Specification: 0.99 Molecular Formula: C27H27F3N2O4S Molecular Weight: 532.57 PubChem CID: 91885560 Isomeric SMILES: C1C[C@@H]([C@H]([C@@H](C1)N2C3=CC=CC=C3CCC4=CC=CC=C42)O)NS(=O)(=O)C5=CC=C(C=C5)OC(F)(F)F